Action on FDA user fee bill delayed
This article was originally published in Clinica
Executive Summary
US House of Representative staff negotiators on a key Food and Drug Administration (FDA) bill have officially called off discussions with their Senate counterparts until September, casting some doubt on whether the government can enact a new law before the agency has to fire some of its workers for lack of funds.